Drugs / Biochaperone Combo
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02915250 | Oct 2016 → Jun 2017 | type 2 diabetes mellitus | Adocia | Completed | Met primary |
| Phase 1 | NCT02514850 | Jul → Nov 2015 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02514954 | Jul → Nov 2015 | type 1 diabetes mellitus | Adocia | Completed | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2019-02-12 | Adocia | Results Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 adocia.com ↗
BioChaperone Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects |
| 2018-09-26 | Adocia | Results Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) adocia.com ↗
Better postprandial glucose control with BioChaperone Combo than with lispro Mix25 or separate glargine and lispro (G+L) administrations in subjects with type 2 diabetes |
| 2018-01-25 | Adocia | Results Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes adocia.com ↗ |
| 2017-06-06 | Adocia | Results Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes adocia.com ↗
Adocia (Euronext Paris: FR0011184241- ADOC), the clinical biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today positive topline results from a Phase 1b clinical trial evaluating the post -meal effects of BioChaperone® Combo in people with type 2 diabetes. |
| 2016-09-08 | Adocia | Results Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting adocia.com ↗
that show a comparable prandial and basal effects compared to the double injection of Lantus® and Humalog® and improved prandial and basal effects vs. Humalog® Mix75/25TM. |
| 2015-11-25 | Adocia | Results Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes adocia.com ↗ |
| 2015-11-04 | Adocia | Results Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes adocia.com ↗ |
| 2014-03-17 | Adocia | Results Adocia: confirmation of positive clinical results Combo adocia.com ↗ |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BioChaperone Combo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02915250 ↗ |
| Route | Subcutaneous | “single subcutaneous doses of 0.8 U/kg Biochaperone® Combo” NCT02514850 ↗ |